Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2113512 | 1.00 | DRD2 (0.48) | DRD2MAPTALOX5NPC1RAB9A | |
| SCHEMBL4873510 | 1.00 | DRD2 (0.48) | DRD2MAPTALOX5NPC1RAB9A | |
| SCHEMBL4908391 | 1.00 | DRD2 (0.48) | DRD2MAPTALOX5NPC1RAB9A | |
| SCHEMBL4651408 | 0.81 | NR1H2 (0.41) | ALDH1A1MEN1KMT2A | |
| SCHEMBL2113831 | 0.81 | NR1H2 (0.41) | ALDH1A1MEN1KMT2A | |
| SCHEMBL4652861 | 0.81 | EPHX2 (0.38) | ALDH1A1MMP9MEN1KMT2A | |
| SCHEMBL5121326 | 0.81 | NR1H2 (0.41) | ALDH1A1MEN1KMT2A | |
| SCHEMBL4652641 | 0.81 | EPHX2 (0.38) | ALDH1A1MMP9MEN1KMT2A | |
| SCHEMBL4651411 | 0.81 | NR1H2 (0.41) | ALDH1A1MEN1KMT2A | |
| SCHEMBL2113457 | 0.81 | EPHX2 (0.38) | ALDH1A1MMP9MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1436249-B1 | MUSCARINIC AGONISTS | LILLY CO ELI (US) | 2013-11-06 | — | — | EP | disclosed |
| US-7326731-B2 | Muscarinic agonists | ELI LILLY AND COMPANY (US) | 2008-02-05 | — | — | US | disclosed |
| US-20040242584-A1 | exemplified by Biphenyl-4-carboxylic acid (R)-(6-(1-((4-fluorobenzyl)methylamino)ethylideneamino) 2(R)-hydroxyindan-1-yl)amide; treating cognitive impairment associated with schizophrenia or Alzheimer's disease | ELI LILLY AND COMPANY | 2004-12-02 | — | — | US | disclosed |
| US-6221876-B1 | 190 KDA MULTIDRUG RESISTANCE PROTEIN (MRP1); 1-AMINO-2-HYDROXYINDAN-6-YL)ISOXAZOLO(3, 4-C)-1,2-DIHYDRO-3-METHYL-6-CHLOROQUINOLIN-2-ONE DERIVATIVES | ELI LILLY AND COMPANY | 2001-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242584-A1 | exemplified by Biphenyl-4-carboxylic acid (R)-(6-(1-((4-fluorobenzyl)methylamino)ethylideneamino) 2(R)-hydroxyindan-1-yl)amide; treating cognitive impairment associated with schizophrenia or Alzheimer's disease | CHRM1, CHRM2, CHRM4 | DRD2 178/4885MAPT 687/4885ALOX5 1829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.